Grace Breeding: what is left of the Brazil route after Sinova

The main article already argued that Brazil is the only arena where Grace holds both a real agronomic need and field results showing that its product works. This follow-up isolates the Brazil route itself: what exactly was built between GAIA, Sinova, and GAPES, what broke in September 2025, and what from that chain was still alive at the start of 2026.

The core thesis is simple: the end of the Sinova relationship did not erase the Brazil story, but it did change its shape. Until September 2025 the company was trying to move from agronomic validation into a launch path through a distributor with real market access. After the breakup with Sinova, it moved back to a slower route built again around research stations, benchmarking, and professional recommendation. That can still lead to commercialization, but as of the report date it was still a validation path, not a sales path.

There is even a built-in paradox here. During 2025 the product proof got stronger, while the proof of the commercial channel got weaker. GAIA delivered strong early data, GAPES delivered comparative validation and an official recommendation, but the station that was supposed to close the gap between trial and market, Sinova, broke along the way. So after Sinova, the question is not whether Maoz works in Brazil. The question is whether Grace still has a credible route that can translate that proof into semi-commercial use and then into a real order.

What GAIA Already Proved

The first step in the chain is also the one that laid the foundation for the whole route. On September 17, 2024 the company received from Eurofins notice of results from seven trials conducted under GAIA supervision in corn fields near Catalão in Goiás, Brazil. The trials were carried out in four replications on a total area of 1,440 square meters, with sowing on February 27, 2024 and harvest on June 24, 2024. The point was not only to show that the product works, but to show that the newer versions require much less material per hectare, are operationally more stable, and do not require cold storage.

This chart matters because it explains why Brazil became a realistic commercial route in the first place. Moving from 20 kg per hectare in Maoz Bio 1 to only 1 kg per hectare in Maoz Bio 5 changes not just the agronomy but also the logistics, production burden, and commercial scalability. The company also says that Maoz Bio 3 and Maoz Bio 5 successfully completed industrial production processes and received local Brazilian licenses. By late 2024 this was no longer just an effective formulation. It was starting to look like a product that could actually be taken into the market.

The story here is sharp. Under full nitrogen, Maoz Bio 5 added 14% to yield and Maoz Bio 3 added 7%. But the more important result sits in the second half of the chart: even with only 50% nitrogen, Maoz Bio 3 added 7% and Maoz Bio 5 added 12%, while Maoz Bio 1 was weaker. For the company, this was the proof that version 5 was not only cheaper to apply, but also the version that should be taken into the commercial route.

There is one more layer that matters. The company writes that the GAIA trials confirmed earlier trials and showed that farmers could save up to 50% of typical urea use, which usually ranges between 150 and 400 kg per hectare, cutting average farmer cost by about $100 per hectare. This is no longer only a lab or yield statement. It is a farmer-economics claim. From this point forward, the challenge was no longer whether there was an effect. It was how to build a route around it.

The Sinova Route: Where the Chain Broke

This is where Sinova enters the story. On October 28, 2024 the company signed a memorandum of understanding with Sinova group. The logic was clear: no longer only controlled validation, but a link to a leading Brazilian agricultural-input distributor with commercial relationships and access to the farming market. This was exactly the step that was supposed to move Grace from “the product works” into “the product can be positioned in front of growers, distributors, and the market.”

The company also describes how it prepared for that step. In February 2025, after deciding together with Sinova not to hold the trials originally planned for the second half of 2024 because of extreme weather and low corn prices between August and November 2024, the effort was shifted into the crop cycle that began in February 2025. Within that framework the company produced and shipped 800 kg of product to Sinova, enough to cover 400 hectares, in order to create a first industrial differentiation between Maoz Bio 3 at 5 kg per hectare and Maoz Bio 5 at 1 kg per hectare. That already looked like a pre-launch step, not just another isolated trial.

This chart is the turning point. On August 7, 2025 the company updated that only 16 trials were actually carried out, each on plots of 5 to 10 hectares, for a total of about 150 hectares, versus an original plan for 25 trials. The quantitative gap matters, but the deeper problem is more important: the company says that because of technical limitations on the farmers’ side, tied to mechanization and agricultural practice suited to larger plots, most of the trials were run at full nitrogen rates of 100%, contrary to the original plan of 50% nitrogen.

This is exactly the point where the commercial route lost quality. If the core thesis behind Maoz is lower nitrogen use without yield damage, and the distributor-run trials no longer test that core protocol, then the route may still formally exist, but it stops producing the kind of proof needed for a launch. It is not accidental that the company adds that it simultaneously began to carry out and fund seven independent farm trials in Brazil that did preserve the original protocol of 25% nitrogen reduction, 50% nitrogen reduction, and a standard treatment.

On September 16, 2025 the formal break arrived. The company announced the end of the commercial relationship with Sinova after identifying competitive activity by UPL, an interested party in Sinova, which launched a competing product named Nuvita there, and after personnel changes at Sinova impaired monitoring of the trials. The company explicitly says that because of that it decided not to rely on the results of the Sinova-run trials and to focus instead on the independent trials.

This is the key analytical point in the whole follow-up: what broke in September 2025 was not the agronomic logic of the product, but the commercial shortcut. Grace did not exit Brazil. It lost the distributor that was supposed to turn proof into market action.

GAPES: The Proof Returned Through a Professional Network

Less than a month later, on October 9, 2025, the company supplied the counterweight. It reported final and significant results from seven trials conducted during the main Brazilian corn season. The trials were carried out through five leading agricultural research stations, while in parallel a broad commercial observation was conducted on 100 hectares in direct farm application.

What did those trials show? In the overwhelming majority of the research-station trials there was no material statistical difference between plots that received standard nitrogen levels and plots treated with only 50% nitrogen combined with the company’s product, and in some cases an additional yield increase was recorded. In the commercial observation, yield rose by 11% versus the control plot. In other words, after the Sinova path broke, the company managed to rebuild the professional case for the product through a stronger experimental setup.

Even more important is the comparative test. GAPES ICT, a Goiás-based group that brings together 44 leading growers, ran a benchmark among nine products, including UTRISHA, which the company identifies as the main competitor. According to the report, Maoz was selected as one of the products with the most impressive result, and the combination of Maoz with 90 nitrogen units delivered better results than treatments with 120 nitrogen units and no product. GAPES then published an official recommendation for its growers to begin commercial use of the product in the following growing season.

This needs to be read with discipline. An official recommendation is a real achievement, but it is still not a revenue line. It means the product crossed another layer of professional legitimacy, and in this case through a meaningful grower network and against competing products. It does not mean Grace had already closed a distribution route or turned the recommendation into contracted demand.

What Is Actually Left of the Brazil Route at the Start of 2026

The last step in the chain arrives on January 13, 2026. Following the GAPES success, the company signed a new agreement with GAPES ICT to conduct an expanded trial series expected to finish in August 2026. That framework includes trials across two sequential crops: soybeans, which generally are not fertilized with nitrogen, and corn, which is sown immediately after soybean harvest and fertilized at much higher levels. The company also says the aim is to test variable Maoz Bio 5 doses, including doses below 1 kg per hectare.

There is a meaningful change in the route here. After Sinova, Grace is no longer trying only to prove that the product can generate a good result in a corn plot. It is trying to enter the actual crop sequence in which the fertilizer decision is made. Beyond the station trials, GAPES growers are expected to conduct semi-commercial trials and observations on their own land covering about 100 to 200 hectares between February and August 2026.

That is what is left of the Brazil route after Sinova: not a perfect route, but not a broken one either. On the one hand, there is no distributor now leading a launch, and the filing does not present a replacement distributor, a disclosed order, or a signed sales route in this thread. On the other hand, there is a cleaner route in terms of proof quality: a professional network, competitor benchmarking, an official recommendation, and a semi-commercial step at a scale far larger than small experimental plots.

That is why 2026 does not read here as a full commercialization year. It reads as an advanced proof year. If the 100 to 200 hectare program finishes on time, if results repeat themselves through the soybean-corn sequence, and if GAPES can turn the recommendation into repeated grower use, Grace will have come out of September 2025 with a credible alternative route. If not, Brazil will remain another year of good trials without a stable commercial bridge.

Bottom Line

After Sinova, what remains in Brazil is stronger product proof, but a shorter market route. GAIA had already shown that nitrogen could be reduced without yield damage, GAPES broadened that proof through five research stations, a 100-hectare observation, and competitor comparison, and the January 2026 agreement pushes the company into a 100 to 200 hectare semi-commercial stage. That is materially more than the company had a year earlier.

But it still does not close the last gap. Sinova was supposed to be the step that connected agronomic outcome to market channel. After the breakup, Grace moved back to a route that starts again from professional recommendation and broader field use. It is a legitimate route, maybe even a cleaner one, but it is also slower and still depends on whether the 2026 semi-commercial use turns into repeat demand rather than just another strong data set.

In other words, Brazil did not come off the table. It simply moved one step back in the commercialization chain. What will determine the 2026 read is no longer the existence of the Maoz effect itself, but whether Grace can rebuild the go-to-market path without another partner that weakens its control over trial design, monitoring, and the commercial message.